Description
Background:
Alnuctamab is a bispecific antibody that has been developed for the treatment of certain types of cancer. It is designed to target two proteins, CD3 and Nectin-4, simultaneously. CD3 is a protein found on the surface of T cells, while Nectin-4 is a protein that is overexpressed in several types of cancer, including bladder cancer and triple-negative breast cancer. By binding to CD3 on T cells and Nectin-4 on cancer cells, alnuctamab brings the two cell types together, leading to T cell activation and subsequent destruction of the cancer cells. This mechanism of action is intended to enhance the immune system’s ability to recognize and eliminate cancer cells.
Intended Use:
For Estimation of Alnuctamab in human serum and plasma. Krishgen’s range of KRIBIOLISA kits are developed using the high quality raw materials and are thoroughly validated for accuracy and precison. They allow quantification of serum or plasma protein drug levels, and can be used for biosimilar and generics research to understand pharmacokinetic properties of the drug. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us for optimisation.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!